What Current Research Says About Fenbendazole and Ivermectin
Fenbendazole and Ivermectin are being studied in early research to determine how they may affect cancer-related processes such as cell growth and metabolism. Most findings come from lab and animal studies, and there is currently no strong evidence supporting their use in human cancer treatment.
Understanding research-based insights on these compounds helps you distinguish early findings from assumptions or online claims. It provides a clearer picture of what is being studied—and what remains uncertain.
Disclaimer: Fenbendazole, Ivermectin, and complementary compounds are not FDA-approved for the treatment of cancer in humans. This article is for educational purposes only and is not intended as medical advice.
Why Fenbendazole & Ivermectin Are Often Discussed Together
Fenbendazole and Ivermectin are often discussed together in cancer research due to their shared origins as antiparasitic compounds and growing interest in drug repurposing.
Their approved uses, however, are very different.
Ivermectin is FDA-approved for human use and also exists in veterinary formulations. In certain controlled settings, human-grade Ivermectin may be used in animals under professional guidance.
Fenbendazole is only for veterinary (animal) use. There is no human-approved version of Fenbendazole.
Although grouped in discussions, these compounds act through distinct biological pathways and are studied separately in research.
Fenbendazole Research
As of 2026, research on Fenbendazole for cancer remains limited, largely based on early studies rather than large human trials.
2025 Case Series (Later Retracted)
The 2025 paper titled "Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients," reported remissions in three advanced cancer patients (breast, prostate, and melanoma).
This case series was later retracted due to an undeclared conflict of interest that affected the interpretation of the findings and is no longer considered reliable.
It did, however, contribute to increased public interest.
2024 Safety Review (Anticancer Research)
A 2024 review published in Anticancer Research, "Oral Fenbendazole for Cancer Therapy in Humans and Animals," identified key challenges, including poor absorption, rapid liver metabolism, and unclear dosing, all of which raise questions about its effectiveness.
Repurposing Benzimidazole Anthelmintic Drugs
Fenbendazole belongs to a group of drugs called benzimidazole anthelmintics. Some related drugs, such as Mebendazole and Albendazole, are FDA-approved for human use and have been explored in research on repurposing benzimidazole anthelmintic drugs for cancer.
Ivermectin Research
Early research on Ivermectin for cancer is mostly limited to preclinical (lab and animal) studies. Human clinical trials remain very limited, with no large randomized trials demonstrating a clear benefit.
2025 Review on Ivermectin
A 2025 review titled "Ivermectin as an Alternative Anticancer Agent" found that ivermectin has a good safety profile with very low toxicity in humans.
In lab and animal studies, it slowed cancer cell growth and reduced tumor size by over 50% in some mice, even at doses below the maximum safe levels defined for humans.
However, these results may not translate to people, and more human trials are needed.
Pre-Clinical Studies on Ivermectin
A small clinical trial presented at the 2025 ASCO Annual Meeting tested Ivermectin combined with immunotherapy (balstilimab) in patients with advanced breast cancer.
Data from 9 patients showed that the combination was safe, with mild side effects. One had a partial response, one had stable disease, and six progressed. The 4-month benefit rate was 37.5%.
Why a Holistic Approach Matters for Cancer Research
Cancer is not a single problem; it involves complex, interconnected disruptions across energy production, cellular communication, and the body's overall balance.
Discover how functional medicine can support cancer care through:
- Advanced testing and personalized assessment
- Supportive care for breast cancer
- Supportive care for ovarian cancer
- Supportive care for prostate cancer
Rather than focusing on isolated findings, functional medicine helps place research into context and better understand how multiple factors influence long-term health outcomes.
Supporting Body Systems Through a Functional Medicine Lens
While the study of repurposed medications is a compelling area of science, these options are most effective when integrated into a data-driven, personal strategy.
At Internal Healing and Wellness MD, we help you move beyond the "search" for answers toward true optimal health. By evaluating your unique health history and biological markers, we provide a holistic approach that respects the rigor of clinical trials while prioritizing your individual path to resolution.
Disclaimer: Fenbendazole, Ivermectin, and complementary compounds are not FDA-approved for the treatment of cancer in humans. This article is for educational purposes only and is not intended as medical advice.
Frequently Asked Questions
Some laboratory studies suggest these drugs may influence cancer cell proliferation in controlled settings, particularly in human cancer cell lines. However, this evidence is limited to preclinical research and does not confirm effects in patients.
Ivermectin has been explored in early-stage studies, including small clinical trials involving breast cancer and other cancers such as lung cancer. These studies are ongoing and have not established a clear clinical benefit.
Neither Fenbendazole nor Ivermectin is approved as an anticancer therapy in the United States, and both are considered experimental. Current evidence does not replace proven therapies used in standard care.
Repurposed drugs are being studied for their potential anti-cancer effects on tumor cells and related pathways. However, these findings require confirmation through rigorous clinical trials.
Aerobic glycolysis is a process linked to cancer metabolism, where cells produce energy in ways that support rapid growth. Some studies explore how compounds may influence this process, but findings remain early-stage.
Fenbendazole is not approved for use in humans, and current evidence is mainly from case reports and limited observations. Its safety and effectiveness have not been established in clinical studies.
Start Understanding Cancer as Part of Whole‑Body Health
When researching emerging topics like Ivermectin and Fenbendazole for cancer, it can be helpful to understand how your overall health may influence your options.
Book your consultation today to explore a comprehensive, holistic path to better health.
Relevant Studies and References
For those interested in learning more about the research, here are several additional resources:
| Study/Source | Key Finding | Link |
|---|---|---|
| American Cancer Society (2024) | What to know about Fenbendazole as a cancer treatment. | American Cancer Society |
| Diniic, J., Efremov, I., Grahovac, J., Podolski-Reniic, A., & Pesic, M. (2024) | Oral fenbendazole for cancer therapy in humans and animals: A review of the literature. Anticancer Research, 44(9), 3725–3736. | Anticancer Research |
| Gao, Y., Xu, C., & Wang, J. (2025) | Ivermectin as an alternative anticancer agent: Current evidence and future perspectives. Pharmaceuticals, 18(10), 1459. | Pharmaceuticals |
| Lee, J. S., & Kim, H. S. (2025) [Retracted] | Fenbendazole as an anticancer agent? A case series of self-administration in three patients. Journal of Cancer Research and Clinical Oncology. | PMC |
| Parikh, A. S., et al. (2025) | Phase I study of ivermectin plus balstilimab in patients with advanced solid tumors, including breast cancer. Journal of Clinical Oncology, 43(16_suppl), e13146. | Journal of Clinical Oncology |
| Tang, A., et al. (2022) | Repurposing benzimidazole anthelmintic drugs as cancer therapeutics. Frontiers in Oncology, 12, 955962. | Frontiers in Oncology |
| WebMD (n.d.) | Ivermectin oral: Uses, side effects, interactions, pictures, warnings & dosing. | WebMD |
